61.98 0.01 (0.02%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 77.08 | 1-year : | 90.03 |
Resists | First : | 66 | Second : | 77.08 |
Pivot price | 61.4 | |||
Supports | First : | 59.7 | Second : | 55.81 |
MAs | MA(5) : | 63.04 | MA(20) : | 60.84 |
MA(100) : | 54.19 | MA(250) : | 41.47 | |
MACD | MACD : | 1.2 | Signal : | 1.1 |
%K %D | K(14,3) : | 65.6 | D(3) : | 73.2 |
RSI | RSI(14): 53.8 | |||
52-week | High : | 66 | Low : | 25.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RDNT ] has closed below upper band by 44.3%. Bollinger Bands are 41.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 63.58 - 63.9 | 63.9 - 64.21 |
Low: | 60.75 - 61.07 | 61.07 - 61.4 |
Close: | 61.47 - 61.97 | 61.97 - 62.49 |
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Sat, 27 Jul 2024
Critical Review: BioNexus Gene Lab (NASDAQ:BGLC) & RadNet (NASDAQ:RDNT) - Defense World
Fri, 26 Jul 2024
UniSuper Management Pty Ltd Makes New $683,000 Investment in RadNet, Inc. (NASDAQ:RDNT) - MarketBeat
Thu, 25 Jul 2024
Bessemer Group Inc. Has $12.18 Million Stake in RadNet, Inc. (NASDAQ:RDNT) - MarketBeat
Wed, 24 Jul 2024
Sei Investments Co. Acquires 10,430 Shares of RadNet, Inc. (NASDAQ:RDNT) - Defense World
Tue, 23 Jul 2024
Clearbridge Investments LLC Buys Shares of 547,004 RadNet, Inc. (NASDAQ:RDNT) - MarketBeat
Mon, 22 Jul 2024
RadNet (NASDAQ:RDNT) Seems To Use Debt Quite Sensibly - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Diagnostics & Research
|
|
Shares Out | 74 (M) |
Shares Float | 65 (M) |
Held by Insiders | 11.1 (%) |
Held by Institutions | 83.9 (%) |
Shares Short | 3,050 (K) |
Shares Short P.Month | 2,990 (K) |
EPS | 0.37 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 11.81 |
Profit Margin | 1.2 % |
Operating Margin | 2.7 % |
Return on Assets (ttm) | 2.3 % |
Return on Equity (ttm) | 6.3 % |
Qtrly Rev. Growth | 10.5 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 22.46 |
EBITDA (p.s.) | 3.12 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 205 (M) |
Levered Free Cash Flow | 62 (M) |
PE Ratio | 167.51 |
PEG Ratio | 7.2 |
Price to Book value | 5.24 |
Price to Sales | 2.75 |
Price to Cash Flow | 22.3 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |